The collaboration leverages Philogen’s DNA-Encoded Chemistry technology and Encoded Self-Assembling Chemical (ESAC) platform.
According to the Swiss-Italian company, the complementary discovery technologies enable the screening of up to billions of small molecules. The technology also optimizes hit compounds in a “fully automatic, DNA-tagged, fragment-based drug discovery manner.”
“Philogen DNA-Encoded libraries are extremely pure and based on smart design in order to provide a rich diversity without the need to work with huge and poorly manageable libraries. Moreover, ESAC technology allows a very fast and efficient way to optimize initial hit compounds and perform lead expansion,” a Philogen representative told Outsourcing-Pharma.com.
“Philogen is delighted to have expanded its ongoing collaborations with Boehringer Ingelheim beyond the area of biologics,” they added.
The companies have previously worked together as part of a collaboration to explore investigate treatment approaches for Acute Myeloid Leukemia (AML).
Financial details of the agreement were not released.